the elderly and in women, as well as the risks for CVD associated with a reduced estimated level of renal function. ese ndings have broad importance to the understanding of the epidemiology of CKD and its consequences and add further to the urgency of a re-evaluation of the performance of eGFR. ey generate questions regarding the utility of renal function-estimating equations based on serum creatinine, such as eGFR-MDRD, for the assessment of renal function in clinical medicine. Clearly, these formulae and their application to epidemiology have helped to heighten awareness of CKD and its complications, but to move forward, new approaches are needed (i) that obviate the use of surrogates for creatinine generation; (ii) that take account of the e ect of age and gender on GFR; and (iii) that use markers for GFR other than creatinine. Perhaps cystatin C or a combination of cystatin C and creatinine will ultimately ful ll this latter role. 22 e eGFR-MDRD and other estimates of renal function based on serum creatinine alone require an objective performance review of their roles in clinical medicine. GFR estimation must evolve into a more precise and accurate art.
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Christopher Winearls (Oxford University) provided invaluable advice in the preparation of this Commentary. In this issue of Kidney International , Horvat and coauthors 1 report on trends in living kidney transplantation in 69 countries, having assembled the data from registries, national societies, and the medical literature. In those countries in which there were no registry data, the authors contacted the transplant centers directly to acquire the data. Assembling worldwide data on live-donor kidney transplants is a commendable accomplishment that serves the international transplant community well. What is now evident in many parts of the world is the reliance on the live donor as the preferred source of the kidney transplant. An explanation for this development is derived from widely known reference data initially compiled by Cecka more than a decade ago. e allogra survival for an unrelated kidney transplant (determined by kidney half-life) is equal to the survival achieved by the transplantation of a kidney from a parent or a child or from a haploidentical sibling (half-lives all approximately 16 years). 2 Moreover, the outcome of transplantation of a kidney from a completely mismatched donor, whether known or anonymous to the recipient, is no di erent from that of a haploidentical match. 3 A better outcome is provided only by an HLA-identical sibling. ese data and the advances in laparoscopic nephrectomy are the factors that probably account for the observations presented in the report by Horvat et al. 1 1 overlooks the experience in neighboring Pakistan and the exploitation that is the reality of organ markets. 5 Nations with ' successful wait list management ' should include the following kinds of data if the program is to serve as a model and the data registry is to be comprehensive:
(i) How many end-stage renal disease patients die (for example, in Iran) each year without gaining access to the list; (ii) e impact of the vendor kidney model on living related kidney transplantation in that country; (iii) e impact of the live-vendor program on deceased donation of hearts and livers and other extrarenal organs not readily obtainable from a live donor.
Among those who wish to present a vendor model as the ideal solution, some also suggest that the program should be ' regulated. ' 6 A component of that regulation is to recommend a xed price for the vendor. In contrast, the opponents of such markets dispute the possibility of xing the vendor payment. 7 For example, in Iran, additional payments are made by the recipient ' s family to the vendor ' s broker that are evidently customary. 8 
THE DECLARATION OF ISTANBUL ON ORGAN TRAFFICKING AND TRANSPLANT TOURISM
In 2004, World Health Assembly Resolution WHA57. 18 urged member states ' to take measures to protect the poorest and vulnerable groups from transplant tourism and the sale of tissues and organs, including attention to the wider problem of international tra cking in human tissues and organs. ' 9 e WHO has estimated that organ trafcking and transplant tourism account for approximately 10 % of organ transplants performed annually around the world. 10 e result of these deliberations was the Declaration of Istanbul on Organ Tra cking and Transplant Tourism. 8 e consensus achieved at the Istanbul Summit was remarkable.
e Istanbul participants emphasized that organ trafcking and transplant tourism should be prohibited because they violate the principles of equity, justice, and respect for human dignity. e Declaration is also clear regarding the consequences of transplant commercialism: ' Because transplant commercialism targets impoverished and otherwise vulnerable donors, it leads inexorably to inequity and injustice and should also be prohibited. To be e ective, these prohibitions must include bans on all types of advertising (electronic and print), soliciting, or brokering for the purpose of transplant commercialism. '
TRANSPLANT TOURISM e report by Horvat et al. 1 suggests appropriately that organ tourism in uences many countries in di erent ways, but the report does not specify how this in uence occurs.
e Istanbul Declaration notes the following regarding transplant tourism: Travel for transplantation is the movement of organs, donors, recipients, or transplantation professionals across jurisdictional borders for transplantation purposes. Travel for transplantation becomes ' transplant tourism ' if it involves organ tra cking and / or transplant commercialism or if the resources (organs, professionals, and transplant centers) devoted to providing transplants to patients from outside a country undermine the country ' s ability to provide transplant services for its own population. 11 Not all recipient travel to a foreign country to undergo transplantation is unethical. Travel for transplantation may be acceptable if the following conditions are ful lled:
For transplantation from a live donor: (i) e recipient has a dual citizenship, in the country of residence and in the destination country, and wishes to undergo transplantation from a live donor who is a family member in the destination country; or (ii) e donor and recipient are genetically or emotionally related and wish to undergo donation and transplantation in a country not of their residence to gain access to better health services. For transplantation from a deceased donor: (i) O cial regulated bilateral or multilateral organ sharing programs exist between or among jurisdictions (countries).
However, travel for transplantation should not result in the denial of organs to people of the destination country because rich people who pay for organs are preferentially cared for, nor should it impede the development of deceased or non-cash-paid live donation in the client country.
THE PREFERENCE FOR THE LIVE DONOR
e data from Cecka cited above also revealed that the outcome of a live-donor transplantation -even unrelated -exceeded the outcome achieved with a deceased donor (half-life of 16 versus 10 years for the deceased-donor transplant). 2 Some have used those data to support unethical national practices.
is report was led on the Internet from the Philippines by Dr Enrique Ona: Of the 690 kidney transplants done in the Philippines in 2006, 158 (23 % ) of these were done for foreign recipients. In 2007, a total of 1046 were done; 536 (51 % ) of these were done in the 13 private hospitals that strongly objected to and ignored the 10 % limit mandated by Philippine Administrative Order. ' Two important facts on living donors have become established. One, it is safe to be a living kidney donor -one lives a normal life in terms of life expectancy, sexual activity, with no or little danger of a higher incidence of hypertension and albuminuria. Two, recipients with live donors have a signi cantly longer survival rate, compared to the best matched deceased donors. e above evidencebased medical facts have added to the tremendous demand of patients with ESRD to seek kidney transplantation as early as possible (pre-emptive), to look for a living donor beyond their family circle, and regardless of racial source. ' 12 
CARE OF THE LIVE DONOR IS NEEDED
Horvat et al. 1 conclude by suggesting that ' communication across nations will continue to put living donation into the global context, enhancing the safety and ethical framework of this practice in the decades to come. ' is is a worthy objective but is hardly assured by a registry unless there is a prospective commitment. e live donor cannot become the target source of kidney transplantation unless proper follow-up is provided, with the same emphasis of care that is a orded the recipient. 13 
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